AlloVir provides updates on phase III clinical development program for posoleucel, an allogeneic virus-specific T cell therapy.
AlloVir, Inc. provided an update on its three Phase III clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).